share_log

Oncolytics Biotech Has Entered Into An Agreement With Leede Jones Gable As Underwriter And Book-runner To Purchase, On A Bought-deal Basis, 6,667,000 Units For Gross Proceeds Of $15M At $2.25/Unit

Oncolytics Biotech Has Entered Into An Agreement With Leede Jones Gable As Underwriter And Book-runner To Purchase, On A Bought-deal Basis, 6,667,000 Units For Gross Proceeds Of $15M At $2.25/Unit

Oncolytics Biotech 已與作爲承銷商和賬簿管理人的 Leede Jones Gable 達成協議,以收購協議的方式購買666.7萬套,總收益爲1500萬美元,每單位2.25美元
Benzinga ·  2023/07/31 06:58

Oncolytics Biotech Has Entered Into An Agreement With Leede Jones Gable As Underwriter And Book-runner To Purchase, On A Bought-deal Basis, 6,667,000 Units For Gross Proceeds Of $15M At $2.25/Unit

Oncolytics Biotech 已與作爲承銷商和賬簿管理人的 Leede Jones Gable 達成協議,以收購協議的方式購買666.7萬套,總收益爲1500萬美元,每單位2.25美元

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論